In February 2004, the company's name was changed from Icogen Corporation to Icogenex Corporation to reflect a refocusing of the business.
Icogenex is using its platform technology ICOCEPTTM to identify therapeutical molecules for the treatment of neurodegenerative diseases involving inappropriate proteolytic processing.
In pursuit of its mission, the company has recruited an experienced research team that has previously made critical contributions to the commercialization of pharmaceutical products, including NovoSeven®, a $1 billion product for Novo Nordisk.
The company's operations have been financed through investments, contract research, and grant support from the National Institutes of Health. The grant funding is a reflection of the high scientific caliber and medical importance of Icogenex projects.
The contract research projects with pharmaceutical companies have demonstrated a proven track record for meeting drug development milestones and timelines. These funds have been invested in developing new technologies, pursuing therapeutic discovery projects, and building the Icogenex operational infrastructure.